Jane Street Group LLC Acquires New Stake in Q32 Bio Inc. (NASDAQ:QTTB)

Jane Street Group LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB) in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 16,437 shares of the company’s stock, valued at approximately $733,000. Jane Street Group LLC owned approximately 0.13% of Q32 Bio at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of QTTB. Values First Advisors Inc. acquired a new position in shares of Q32 Bio during the third quarter worth about $33,000. BNP Paribas Financial Markets lifted its stake in Q32 Bio by 199.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock valued at $58,000 after acquiring an additional 864 shares in the last quarter. Rhumbline Advisers boosted its position in Q32 Bio by 11,681.5% during the 2nd quarter. Rhumbline Advisers now owns 7,658 shares of the company’s stock worth $137,000 after acquiring an additional 7,593 shares during the last quarter. MetLife Investment Management LLC bought a new position in shares of Q32 Bio during the 3rd quarter worth approximately $159,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Q32 Bio in the second quarter valued at approximately $265,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on QTTB shares. Leerink Partners restated a “market perform” rating and set a $9.00 target price (down previously from $68.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Piper Sandler decreased their price objective on Q32 Bio from $85.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Raymond James reaffirmed an “outperform” rating and issued a $22.00 target price (down previously from $90.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. BMO Capital Markets reduced their price target on Q32 Bio from $64.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday, December 12th. Finally, Oppenheimer lowered their price target on Q32 Bio from $80.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

Q32 Bio Stock Performance

Shares of NASDAQ QTTB opened at $3.45 on Friday. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $42.02 million, a P/E ratio of -0.24 and a beta of -0.46. Q32 Bio Inc. has a 12 month low of $3.02 and a 12 month high of $53.79. The stock has a 50 day moving average of $25.33 and a 200-day moving average of $32.40.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.